Enhancer of Revascularization, Gene and Stem Cell Therapies

  • Koji Tokunaga
  • Isao Date


Various surgical techniques for direct or indirect vasoreconstruction have been developed for moyamoya disease [1– 6]. The induction of neovascularization can be achieved in most patients by indirect surgery on the brain surface through vascularized tissues such as the galea, the dura mater, and the temporal muscle [7, 8], although the development of neovascularization after indirect surgery is slower than that induced by direct bypass and not sufficient in some patients. The results of direct bypass are not always excellent in terms of the extent of blood supply and the long-term patency [9]. Adjunctive therapies to enhance neovascularization after indirect surgery may improve the angiographic and clinical results of patients with moyamoya disease.


Vascular Endothelial Growth Factor Cerebral Ischemia Hepatocyte Growth Factor Middle Cerebral Artery Occlusion Bone Marrow Stromal Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Karasawa J, Kikuchi H, Furuse S et al (1977) A surgical treatment of “moyamoya” disease “enceph-alo-myo synangiosis”. Neurol Med Chir (Tokyo) 17:29–37CrossRefGoogle Scholar
  2. 2.
    Matsushima Y, Fukai N, Tanaka K et al (1981) A new surgical treatment of moyamoya disease in children: a preliminary report. Surg Neurol 15:313–320PubMedCrossRefGoogle Scholar
  3. 3.
    Kinugasa K, Mandai S, Tokunaga K et al (1994) Ribbon enchephalo-duro-arterio-myo-synangiosis for moyamoya disease. Surg Neurol 41:455–461PubMedCrossRefGoogle Scholar
  4. 4.
    Kinugasa K, Mandai S, Kamata I et al (1993) Surgical treatment of moyamoya disease: operative technique for encephalo-duro-arterio-myo-synangiosis, its follow-up, clinical results, and angio-grams. Neurosurgery 32:527–531PubMedCrossRefGoogle Scholar
  5. 5.
    Karasawa J, Kikuchi H, Furuse S et al (1978) Treatment of moyamoya disease with STA-MCA anastomosis. J Neurosurg 49:679–688PubMedCrossRefGoogle Scholar
  6. 6.
    Tokunaga K, Kinugasa K, Mandai S et al (1994) Ribbon encephalo-duro-arterio-myo-synangiosis (ribbon EDAMS) for patients with moyamoya disease. Nerv Syst Child 19:131–137Google Scholar
  7. 7.
    Kawaguchi T, Fujita S, Hosoda K et al (1996) Multiple burr-hole operation for adult moyamoya disease. J Neurosurg 84:468–476PubMedCrossRefGoogle Scholar
  8. 8.
    Isono M, Ishii K, Kobayashi H et al (2002) Effects of indirect bypass surgery for occlusive cerebro-vascular diseases in adults. J Clin Neurosci 9:644–647PubMedCrossRefGoogle Scholar
  9. 9.
    Houkin K, Kuroda S, Ishikawa T et al (2000) Neovascularization (angiogenesis) after revasculariza-tion in moyamoya disease. Which technique is most useful for moyamoya disease? Acta Neurochir (Wien) 142:269–276CrossRefGoogle Scholar
  10. 10.
    Date I, Yasuhara T (2009) Neurological disorders and neural regeneration, with special reference to Parkinson's disease and cerebral ischemia. J Artif Organs 12:11–16PubMedCrossRefGoogle Scholar
  11. 11.
    Yano A, Shingo T, Takeuchi A et al (2005) Encapsulated vascular endothelial growth factor-secreting cell grafts have neuroprotective and angiogenic effects on focal cerebral ischemia. J Neurosurg 103:104–114PubMedCrossRefGoogle Scholar
  12. 12.
    Muraoka K, Shingo T, Yasuhara T et al (2008) Comparison of the therapeutic potential of adult and embryonic neural precursor cells in a rat model of Parkinson disease. J Neurosurg 108:149–159PubMedCrossRefGoogle Scholar
  13. 13.
    Muraoka K, Shingo T, Yasuhara T et al (2006) The high integration and differentiation potential of autologous neural stem cell transplantation compared with allogeneic transplantation in adult rat hippocampus. Exp Neurol 199:311–327PubMedCrossRefGoogle Scholar
  14. 14.
    Kusaka N, Sugiu K, Tokunaga K et al (2005) Enhanced brain angiogenesis in chronic cerebral hypoperfusion after administration of plasmid human vascular endothelial growth factor in combination with indirect vasoreconstructive surgery. J Neurosurg 103:882–890PubMedCrossRefGoogle Scholar
  15. 15.
    Ogawa T, Ono S, Ichikawa T et al (2007) Novel protein transduction method by using 11R: an effective new drug delivery system for the treatment of cerebrovascular diseases. Stroke 38:1354–1361PubMedCrossRefGoogle Scholar
  16. 16.
    Takahashi K, Tanabe K, Ohnuki M et al (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:861–872PubMedCrossRefGoogle Scholar
  17. 17.
    Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669–676PubMedCrossRefGoogle Scholar
  18. 18.
    Harrigan MR (2003) Angiogenic factors in the central nervous system. Neurosurgery 53:639–660; discussion 660–631PubMedCrossRefGoogle Scholar
  19. 19.
    Baumgartner I, Pieczek A, Manor O et al (1998) Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 97:1114–1123PubMedCrossRefGoogle Scholar
  20. 20.
    Isner JM, Pieczek A, Schainfeld R et al (1996) Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 348:370–374PubMedCrossRefGoogle Scholar
  21. 21.
    Losordo DW, Vale PR, Symes JF et al (1998) Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 98:2800–2804PubMedCrossRefGoogle Scholar
  22. 22.
    Ozawa CR, BanfiA, Glazer NL et al (2004) Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. J Clin Invest 113:516–527PubMedGoogle Scholar
  23. 23.
    Takeshita S, Weir L, Chen D et al (1996) Therapeutic angiogenesis following arterial gene transfer of vascular endothelial growth factor in a rabbit model of hindlimb ischemia. Biochem Biophys Res Commun 227:628–635PubMedCrossRefGoogle Scholar
  24. 24.
    Tsurumi Y, Kearney M, Chen D et al (1997) Treatment of acute limb ischemia by intramuscular injection of vascular endothelial growth factor gene. Circulation 96:II-382–388Google Scholar
  25. 25.
    Tanaka K, Wada N, Hori K et al (1998) Chronic cerebral hypoperfusion disrupts discriminative behavior in acquired-learning rats. J Neurosci Methods 84:63–68PubMedCrossRefGoogle Scholar
  26. 26.
    Kim HJ, Jang SY, Park JI et al (2004) Vascular endothelial growth factor-induced angiogenic gene therapy in patients with peripheral artery disease. Exp Mol Med 36:336–344PubMedCrossRefGoogle Scholar
  27. 27.
    Yasuhara T, Shingo T, Muraoka K et al (2005) The differences between high and low-dose administration of VEGF to dopaminergic neurons of in vitro and in vivo Parkinson's disease model. Brain Res 1038:1–10PubMedCrossRefGoogle Scholar
  28. 28.
    Kim I, Moon SO, Park SK et al (2001) Angiopoietin-1 reduces VEGF-stimulated leukocyte adhesion to endothelial cells by reducing ICAM-1, VCAM-1, and E-selectin expression. Circ Res 89:477–479PubMedCrossRefGoogle Scholar
  29. 29.
    Thurston G, Rudge JS, Ioffe E et al. (2000) Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 6:460–463PubMedCrossRefGoogle Scholar
  30. 30.
    Chae JK, Kim I, Lim ST et al (2000) Coadministration of angiopoietin-1 and vascular endothelial growth factor enhances collateral vascularization. Arterioscler Thromb Vasc Biol 20:2573–2578PubMedCrossRefGoogle Scholar
  31. 31.
    Shyu KG, Chang H, Isner JM (2003) Synergistic effect of angiopoietin-1 and vascular endothelial growth factor on neoangiogenesis in hypercholesterolemic rabbit model with acute hindlimb ischemia. Life Sci 73:563–579PubMedCrossRefGoogle Scholar
  32. 32.
    Morishita R, Aoki M, Hashiya N et al (2004) Safety evaluation of clinical gene therapy using hepa-tocyte growth factor to treat peripheral arterial disease. Hypertension 44:203–209PubMedCrossRefGoogle Scholar
  33. 33.
    Yoshimura S, Morishita R, Hayashi K et al (2002) Gene transfer of hepatocyte growth factor to suba-rachnoid space in cerebral hypoperfusion model. Hypertension 39:1028–1034PubMedCrossRefGoogle Scholar
  34. 34.
    Kameda M, Shingo T, Takahashi K et al (2007) Adult neural stem and progenitor cells modified to secrete GDNF can protect, migrate and integrate after intracerebral transplantation in rats with transient forebrain ischemia. Eur J Neurosci 26:1462–1478PubMedCrossRefGoogle Scholar
  35. 35.
    Woodbury D, Schwarz EJ, Prockop DJ et al (2000) Adult rat and human bone marrow stromal cells differentiate into neurons. J Neurosci Res 61:364–370PubMedCrossRefGoogle Scholar
  36. 36.
    Bang OY, Lee JS, Lee PH et al (2005) Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol 57:874–882PubMedCrossRefGoogle Scholar
  37. 37.
    Taguchi A, Soma T, Tanaka H et al (2004) Administration of CD34+ cells after stroke enhances neurogenesis via angiogenesis in a mouse model. J Clin Invest 114:330–338PubMedGoogle Scholar

Copyright information

© Springer 2010

Authors and Affiliations

  1. 1.Department of Neurological SurgeryOkayama University Graduate School of Medicine, Dentistry and Pharmaceutical SciencesKita-kuJapan

Personalised recommendations